Notes
MHRA = Medicines and Healthcare products Regulatory Authority
Reference
Medicines and Healthcare products Regulatory Agency (UK). Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors. Internet Document : 26 Aug 2020. Available from: URL: https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors
Rights and permissions
About this article
Cite this article
Increased risk of diverticulitis + GI perforation with baricitinib. Reactions Weekly 1821, 1 (2020). https://doi.org/10.1007/s40278-020-83121-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-83121-8